Network meta-analysis of triple immunosuppressive therapies and standard of care for induction of remission of active lupus nephritis.
LupusAug 5, 2026 (epub)
Gabriel Contreras, Vinodh Mechery, Sanjana Kota et al.
✦ AI-curated · Sources linked
In 30 seconds
This network meta-analysis evaluated the efficacy and safety of eight triple immunosuppressive therapies compared to standard of care (SOC) in patients with active lupus nephritis. The analysis found that SOC combined with Tacrolimus, Voclosporin, Obinutuzumab, and Belimumab significantly improved primary renal remission rates without increasing the risk of serious adverse events. The benefit ratio for SOC+Tacrolimus was 1.91.
Key findings
- SOC+Tacrolimus showed a benefit ratio of 1.91 for primary renal remission compared to SOC alone.
- SOC+Voclosporin had a benefit ratio of 1.69 for achieving primary renal remission.
- SOC+Obinutuzumab and SOC+Belimumab had benefit ratios of 1.41 and 1.32, respectively.
- No significant differences in serious adverse events or serious infectious events among therapies.
Why it matters
Understanding the comparative effectiveness of triple immunosuppressive therapies can guide clinicians in selecting optimal treatment strategies for patients with active lupus nephritis, potentially improving patient outcomes.